The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
Open accessAbstract
SUMMARY: The increased use of antibacterial and antifungal agents in recent years has resulted in the development of resistance to these drugs. The significant clinical implication of resistance has led to heightened interest in the study of antimicrobial resistance from different angles. Areas addressed include mechanisms underlying this resistance, improved methods to detect resistance when it occurs, alternate options for the treatment of infections caused by resistant organisms, and strategies to prevent and control the emergence and spread of resistance. In this review, the mode of action of antifungals and their mechanisms of resistance are discussed. Additionally, an attempt is made to discuss the correlation between fungal and bacterial resistance. Antifungals can be grouped into three classes based on their site of action: azoles, which inhibit the synthesis of ergosterol (the main fungal sterol); polyenes, which interact with fungal membrane sterols physicochemically; and 5-fluorocytosine, which inhibits macromolecular synthesis. Many different types of mechanisms contribute to the development of resistance to antifungals. These mechanisms include alteration in drug target, alteration in sterol biosynthesis, reduction in the intercellular concentration of target enzyme, and overexpression of the antifungal drug target. Although the comparison between the mechanisms of resistance to antifungals and antibacterials is necessarily limited by several factors defined in the review, a correlation between the two exists. For example, modification of enzymes which serve as targets for antimicrobial action and the involvement of membrane pumps in the extrusion of drugs are well characterized in both the eukaryotic and prokaryotic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“These transporters have a common four-core domain structure (49) consisting of two integral membrane domains that span the membrane multiple times and two ATP-binding cytoplasmic domains that couple ATP hydrolysis to substrate transport (60).”
BackgroundBIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era
Cohen, M. L. (1992) · Science · doi:10.1126/science.257.5073.1050 · Cited by 1,304
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Cited by
Hyldgaard, M., Mygind, T., & Meyer, R. L. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00012 · Cited by 2,191
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00278.x · Cited by 969
The biology and chemistry of antifungal agents: A review
Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.045 · Cited by 664
Borkovich, K. A., Alex, L. A., Yarden, O., Freitag, M., Turner, G. E., Read, N. D., Seiler, S., Bell-Pedersen, D., Paietta, J., Plesofsky, N., et al. (2004) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.68.1.1-108.2004 · Cited by 621
Antifungal drug resistance of pathogenic fungi
Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511
“albicans is a cytochrome P-450 hemoprotein involved in the ergosterol biosynthetic pathway (19).”
BackgroundSelf-citationAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Pathogenesis of Candida albicans biofilm
Tsui, C., Kong, E. F., & Jabra-Rizk, M. A. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw018 · Cited by 481
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Anti-Fungal Efficacy and Mechanisms of Flavonoids
Al Aboody, M. S., & Mickymaray, S. (2020) · Antibiotics · doi:10.3390/antibiotics9020045 · Cited by 472
FLO1 Is a Variable Green Beard Gene that Drives Biofilm-like Cooperation in Budding Yeast
Smukalla, S., Caldara, M., Pochet, N., Beauvais, A., Guadagnini, S., Yan, C., Vinces, M. D., Jansen, A., Prevost, M. C., Latgé, J.-P., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.037 · Cited by 452
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citationKoch, A., Kumar, N., Weber, L., Keller, H., Imani, J., & Kogel, K.-H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306373110 · Cited by 431
Similarities and differences in the responses of microorganisms to biocides
Russell, A. D. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg422 · Cited by 393
Biofilm of Candida albicans : formation, regulation and resistance
Pereira, R., Santos Fontenelle, R. O., Brito, E. H. S., & Morais, S. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14949 · Cited by 368
Molecular architecture of fungal cell walls revealed by solid-state NMR
Kang, X., Kirui, A., Muszyński, A., Widanage, M. C. D., Chen, A., Azadi, P., Wang, P., Mentink-Vigier, F., & Wang, T. (2018) · Nature Communications · doi:10.1038/s41467-018-05199-0 · Cited by 356
Membrane targeting cationic antimicrobial peptides
Ciumac, D., Gong, H., Hu, X., & Lu, J. R. (2019) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.10.103 · Cited by 351
Cinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 345
Antimicrobial Metal Nanomaterials: From Passive to Stimuli‐Activated Applications
Cheeseman, S., Christofferson, A. J., Kariuki, R., Cozzolino, D., Daeneke, T., Crawford, R. J., Truong, V. K., Chapman, J., & Elbourne, A. (2020) · Advanced Science · doi:10.1002/advs.201902913 · Cited by 337
Clinical Appearance of Oral Candida Infection and Therapeutic Strategies
Patil, S., Rao, R. S., Majumdar, B., & Anil, S. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01391 · Cited by 324
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322
“Indeed, resistance to triazoles emerges frequently and, although echinocandins are relatively new to the clinic, resistance to echinocandins is also already arising [13–18].”
BackgroundPfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug
Mesa-Arango, A. C., Scorzoni, L., & Zaragoza, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00286 · Cited by 311
“…in resistance to this compound (Kim and Kwon-Chung, 1974; Kim et al., 1974; Woods et al., 1974; Safe et al., 1977; Drutz and Lehrer, 1978; Merz and Sandford, 1979; Kreiner et al., 1993; Kelly et al., 1994; Currie et al., 1995; Ghannoum and Rice, 1999; Walsh et al., 2003; Vandeputte et al., 2007).”
BackgroundCombination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Self-citationCurcumin as a promising antifungal of clinical interest
Martins, C. V. B., da Silva, D. L., Neres, A. T. M., Magalhaes, T. F. F., Watanabe, G. A., Modolo, L. V., Sabino, A. A., de Fatima, A., & de Resende, M. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn488 · Cited by 302
Regulation of multidrug resistance in pathogenic fungi
Morschhäuser, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.08.002 · Cited by 300
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
An update on antifungal targets and mechanisms of resistance in Candidaalbicans
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291
Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine
Mukherjee, P. K., Leidich, S. D., Isham, N., Leitner, I., Ryder, N. S., & Ghannoum, M. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.82-86.2003 · Cited by 291
Self-citationVermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285
“Uncharacterized factors other than CDR1-PDH1 upregulation, such as coding sequence mutations in ERG11, could potentially contribute to azole resistance in the clinical isolates studied here ( 18 ).”
BackgroundWelscher, Y. M. T., Napel, H. H. T., Balagué, M. M., Souza, C. M., Riezman, H., de Kruijff, B., & Breukink, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707821200 · Cited by 274
Falaise, C., François, C., Travers, M.-A., Morga, B., Haure, J., Tremblay, R., Turcotte, F., Pasetto, P., Gastineau, R., Hardivillier, Y., et al. (2016) · Marine Drugs · doi:10.3390/md14090159 · Cited by 253
Al-Tel, T. H., Al-Qawasmeh, R. A., & Zaarour, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.051 · Cited by 252
Zhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609370104 · Cited by 248
Development of the CRISPR/Cas9 System for Targeted Gene Disruption in Aspergillus fumigatus
Fuller, K. K., Chen, S., Loros, J. J., & Dunlap, J. C. (2015) · Eukaryotic Cell · doi:10.1128/ec.00107-15 · Cited by 244
Analysis of Growth Characteristics of Filamentous Fungi in Different Nutrient Media
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., & Verweij, P. E. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.2.478-484.2001 · Cited by 241
Mesa-Arango, A. C., Trevijano-Contador, N., Román, E., Sánchez-Fresneda, R., Casas, C., Herrero, E., Argüelles, J. C., Pla, J., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03570-14 · Cited by 232
Bhattacharya, S., Esquivel, B. D., & White, T. C. (2018) · mBio · doi:10.1128/mbio.01291-18 · Cited by 210
“sterol composition have been shown previously to have polyene resistance (40).”
BackgroundAgarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., & Clark, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306291200 · Cited by 204
Hagiwara, D., Miura, D., Shimizu, K., Paul, S., Ohba, A., Gonoi, T., Watanabe, A., Kamei, K., Shintani, T., Moye-Rowley, W. S., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006096 · Cited by 156
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
Echinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Hasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144
Microalgal Cell Biofactory—Therapeutic, Nutraceutical and Functional Food Applications
Kiran, B. R., & Venkata Mohan, S. (2021) · Plants · doi:10.3390/plants10050836 · Cited by 124
Antifungal activity of thiosemicarbazones, bis(thiosemicarbazones), and their metal complexes
Bajaj, K., Buchanan, R. M., & Grapperhaus, C. A. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111620 · Cited by 122
Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action
Hillenmeyer, M. E., Ericson, E., Davis, R. W., Nislow, C., Koller, D., & Giaever, G. (2010) · Genome Biology · doi:10.1186/gb-2010-11-3-r30 · Cited by 112
“Nystatin is known to bind to membrane ergosterol, and it causes cell death by creating pores in the plasma membrane [50].”
BackgroundRecent Approaches to Antifungal Therapy for Invasive Mycoses
Mathew, B. P., & Nath, M. (2009) · ChemMedChem · doi:10.1002/cmdc.200800353 · Cited by 105
Khot, P. D., Suci, P. A., Miller, R. L., Nelson, R. D., & Tyler, B. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00997-06 · Cited by 104
“albicans to acquire resistance to AmB (29).”
BackgroundAlves, C. T., Ferreira, I. C., Barros, L., Silva, S., Azeredo, J., & Henriques, M. (2014) · Future Microbiology · doi:10.2217/fmb.13.147 · Cited by 102
Hayes, B. M. E., Anderson, M. A., Traven, A., van der Weerden, N. L., & Bleackley, M. R. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1573-8 · Cited by 93
“These differences in signalling may be due to different targets for these drugs in the ergosterol biosynthesis pathway (ERG11 for fluconazole, ERG1 for terbinafine and ERG2 for fenpropimorph) [75, 91, 92].”
BackgroundUnraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84
“It is also notable that the target of azole antifungals, lanosterol 14-demethylase (Ghannoum and Rice, 1999) is conserved from yeast to human.”
Acquired multidrug antifungal resistance in Candida lusitaniae during therapy
Asner, S. A., Giulieri, S., Diezi, M., Marchetti, O., & Sanglard, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-15 · Cited by 82
UPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00221-13 · Cited by 71
“Integration of these sterols into the plasma membrane disrupts its integrity, resulting in its altered structure and function (12, 43, 44).”
BackgroundRuy, F., Vercesi, A. E., & Kowaltowski, A. J. (2006) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9012-7 · Cited by 74
Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide
Hein, K. Z., Takahashi, H., Tsumori, T., Yasui, Y., Nanjoh, Y., Toga, T., Wu, Z., Grötzinger, J., Jung, S., Wehkamp, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511197112 · Cited by 74
“Polyene antifungals bind to ergosterol in the fungal cell membrane, forming transmembrane channels that lead to monovalent ion leakage (32).”
BackgroundNagi, M., Nakayama, H., Tanabe, K., Bard, M., Aoyama, T., Okano, M., Higashi, S., Ueno, K., Chibana, H., Niimi, M., et al. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01470.x · Cited by 68
Dickwella Widanage, M. C., Gautam, I., Sarkar, D., Mentink-Vigier, F., Vermaas, J. V., Ding, S.-Y., Lipton, A. S., Fontaine, T., Latgé, J.-P., Wang, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50799-8 · Cited by 70
“There are currently a few antifungal agents available, with often therapeutic failures and a recently observed increase in drug resistance 6 – 9 .”
New antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Chew, S. Y., & Than, L. T. L. (2016) · Mycoses · doi:10.1111/myc.12455 · Cited by 63
Trakranrungsie, N., Chatchawanchonteera, A., & Khunkitti, W. (2008) · Research in Veterinary Science · doi:10.1016/j.rvsc.2007.03.006 · Cited by 62
Eldesouky, H. E., Salama, E. A., Li, X., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64571-7 · Cited by 55
Gamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58
Self-citationThe mode of the antifungal activity of gemini-pyridinium salt against yeast
SHIRAI, A., SUMITOMO, T., KURIMOTO, M., MASEDA, H., & KOURAI, H. (2009) · Biocontrol Science · doi:10.4265/bio.14.13 · Cited by 53
Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs
Eldesouky, H. E., Mayhoub, A., Hazbun, T. R., & Seleem, M. N. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-17 · Cited by 55
Kim, J., Cho, Y.-J., Do, E., Choi, J., Hu, G., Cadieux, B., Chun, J., Lee, Y., Kronstad, J. W., & Jung, W. H. (2012) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2012.08.006 · Cited by 53
Holbrook, S. Y. L., Garzan, A., Dennis, E. K., Shrestha, S. K., & Garneau-Tsodikova, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.030 · Cited by 51
UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata
Whaley, S. G., Caudle, K. E., Vermitsky, J.-P., Chadwick, S. G., Toner, G., Barker, K. S., Gygax, S. E., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02217-13 · Cited by 52
Dickwella Widanage, M. C., Singh, K., Li, J., Yarava, J. R., Scott, F. J., Xu, Y., Gow, N. A. R., Mentink-Vigier, F., Wang, P., Lamoth, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61678-1 · Cited by 51
Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., & Teixeira, M. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135110 · Cited by 46
“The antifungal drug 5-flucytosine is a fluorinated pyrimidine which enters fungal cells through one or more permeases [3,4,5] and is then converted, by cytosine deaminase, to its metabolically active form 5-fluorouracil (5-FU) [3,4,6].”
BackgroundBen Othmène, Y., Monceaux, K., Belhadef, A., Karoui, A., Ben Salem, I., Boussabbeh, M., Abid-Essefi, S., & Lemaire, C. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2022.103919 · Cited by 43
Localizing Antifungal Drugs to the Correct Organelle Can Markedly Enhance their Efficacy
Benhamou, R. I., Bibi, M., Berman, J., & Fridman, M. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802509 · Cited by 42
Fluoride enhances the activity of fungicides that destabilize cell membranes
Li, S., & Breaker, R. R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.03.006 · Cited by 36
De Cremer, K., De Brucker, K., Staes, I., Peeters, A., Van den Driessche, F., Coenye, T., Cammue, B. P. A., & Thevissen, K. (2016) · Scientific Reports · doi:10.1038/srep27463 · Cited by 34
Heasley, B. H., Pacofsky, G. J., Mamai, A., Liu, H., Nelson, K., Coti, G., Peel, M. R., Balkovec, J. M., Greenlee, M. L., Liberator, P., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.031 · Cited by 35
Eldesouky, H. E., Salama, E. A., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-62976-y · Cited by 33
Ribeiro, M. A., Paula, C. R., Perfect, J. R., & Cox, G. M. (2005) · Medical Mycology · doi:10.1080/13693780500093838 · Cited by 27
Antibacterial and antifungal drug discovery
Persidis, A. (1999) · Nature Biotechnology · doi:10.1038/15141 · Cited by 22
Functional characterization of the Aspergillus fumigatus PHO80 homologue
de Gouvêa, P. F., Soriani, F. M., Malavazi, I., Savoldi, M., Goldman, M. H. D. S., Loss, O., Bignell, E., da Silva Ferreira, M. E., & Goldman, G. H. (2008) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.04.001 · Cited by 21
Influence of Iron Regulation on the Metabolome of Cryptococcus neoformans
Choi, J. N., Kim, J., Kim, J., Jung, W. H., & Lee, C. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041654 · Cited by 18
“Iron, as form of heme, is known to influence the synthesis of ergosterol because two enzymes, Erg5 and Erg11 encoding C-22 desaturase and C14a-methyl sterol demethylase respectively, belong to the heme containing cytochrome P450 protein family [21].”
BackgroundCandida auris biofilm: a review on model to mechanism conservation
Khari, A., Biswas, B., Gangwar, G., Thakur, A., & Puria, R. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2179036 · Cited by 18
Rashid, S., Correia-Mesquita, T. O., Godoy, P., Omran, R. P., & Whiteway, M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.764711 · Cited by 15
ALCZUK, S. D. S. D., BONFIM-MENDONÇA, P. D. S., ROCHA-BRISCHILIARI, S. C., SHINOBU-MESQUITA, C. S., MARTINS, H. P. R., GIMENES, F., ABREU, A. L. P. D., CARVALHO, M. D. D. B., PELLOSO, S. M., SVIDZINSKI, T. I. E., et al. (2015) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652015000200012 · Cited by 15
Aneuploidy Underlies Brefeldin A‐Induced Antifungal Drug Resistance in Cryptococcus Neoformans
Zhang, Z.-H., Sun, L.-L., Fu, B.-Q., Deng, J., Jia, C.-L., Miao, M.-X., Yang, F., Cao, Y.-B., & Yan, T.-H. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1397724 · Cited by 14
Nitrogen concentration affects amphotericin B and fluconazole tolerance of pathogenic cryptococci
Bosch, C., Toplis, B., Vreulink, J.-M., Volschenk, H., & Botha, A. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa010 · Cited by 12
Flucytosine: Site of Action, Mechanism of Resistance and Use in Combination Therapy
Chandra, J., Mohammad, S., & Ghannoum, M. A. (2009) · Antimicrobial Drug Resistance · doi:10.1007/978-1-59745-180-2_27 · Cited by 6
Metadata
- Authors
- Ghannoum, M. A., & Rice, L. B.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 1999-10
- Volume
- 12
- Issue
- 4
- Pages
- 501-517
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2144149632
- Cited by
- 1,785
- References
- 118
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.